DVA Stock Recent News

A ransomware attack that encrypted certain elements of dialysis firm DaVita's network affected 2.7 million people, the U.S. health department's website showed on Thursday.

DaVita has reduced the share count by over 10% in the last six months, but interest expenses increased by 50% Y/Y. International revenues grew by 36% Y/Y, and DaVita is pending regulatory approval to close an acquisition from Fresenius Medical Care AG in Brazil. In the U.S., volumes declined by 1.1% Y/Y during Q2 2025 due to missed treatments caused by the severe flu season and the April cyber attack.

Warren Buffett is one of the most celebrated investors of our time. The famed chief executive officer of Berkshire Hathaway, who will celebrate his 95th birthday on Aug. 30, is finally retiring from the conglomerate after a 60-year career in which he made Berkshire one of the biggest publicly traded companies in the world.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Continued Vafseo® (vadadustat) growth with Q2 2025 net product revenues increasing to $13.3 million ; Total Q2 2025 net product revenues increased to $60.5 million DaVita physicians are expected to begin treating patients with Vafseo in August 2025 as part of an operational pilot at 100+ DaVita dialysis clinics Patient enrollment completed in VOICE, a collaborative clinical trial of Vafseo conducted by USRC Akebia to host Conference Call at 8:00 a.m. ET on Thursday, August 7, 2025 CAMBRIDGE, Mass.

DVA reports strong second-quarter 2025 results with earnings and revenue beat, along with a boost in gross margin, driven by core operations.

DaVita Inc. (NYSE:DVA ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Javier J. Rodriguez - CEO & Executive Director Joel Ackerman - CFO & Treasurer Nic Eliason - Group Vice President of Investor Relations Conference Call Participants Albert J.

DaVita HealthCare (DVA) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estimate of $2.7 per share. This compares to earnings of $2.59 per share a year ago.

DaVita beat Wall Street estimates for second-quarter profit on Tuesday, driven by demand for its kidney dialysis services.